Influencing factors for hemolytic anemia in patients with chronic hepatitis C treated by ribavirin combined with pegylated interferon-α
Objective To investigate the influencing factors for ribavirin (RBV)-induced hemolytic anemia during the treatment of chronic hepatitis C using RBV combined with pegylated interferon-α (PEG-IFNα), and to provide a reference for early prediction of RBV-related hemolytic anemia in clinical practice. M...
Main Author: | XU Jinfeng |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Department of Journal of Clinical Hepatology
2019-02-01
|
Series: | Linchuang Gandanbing Zazhi |
Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=9595 |
Similar Items
-
Chronic hepatitis C successfully treated with telaprevir, pegylated interferon and ribavirin in severe aplastic anemia
by: Ilker I. Balkan, et al.
Published: (2014-11-01) -
Predictors of anemia associated with pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C
by: Ta-Wei Chen, et al.
Published: (2011) -
Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
by: Yasser K. Rashed, et al.
Published: (2020-02-01) -
Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
by: Roberto J Carvalho-Filho, et al.
Published: (2010-03-01) -
Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirin
by: Dalia H.A.R Khalil, et al.
Published: (2016-01-01)